Chromoblastomycosis Treatment Market Research Report -Forecast to 2027

Chromoblastomycosis Treatment Market Research Report: by Species (f. Pedrosoi, c. Carrionii, p. Verrucosa, f. Compacta, r. Aquaspersa, c. Funicola), Types (nodular, tumoral, verrucous, plaque), Treatment, Diagnosis, End-User – global forecast till 2027

ID: MRFR/Pharma/4230-HCR | February 2021 | Region: Global | 120 pages         

Chromoblastomycosis Treatment Market Speak to Analyst Request a Free Sample

Chromoblastomycosis Treatment Market Scenario:


Chromoblastomycosis is a fungal infection caused by species such as Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola and others. This disease mostly affects the skin and the subcutaneous tissues. Globally, there is about a million type of fungal species, yet nearly 300 are capable of causing infections or disease in humans. Most of these cases are seen in people with compromised immune systems and can occur almost in any part of the body.


A type of fungal infection known as systemic mycosis is affecting the internal organs of the body. During this, fungal infection can spread and affect other organs of the body. The rising cases of immunological diseases is a reason for increased probability of systemic mycosis. Thus, the developing novel treatment for chromoblastomycosis with fewer side effects is the primary objective of manufacturing companies.


The newly launched azoles such as voriconazole and itraconazole, are the gold standard drugs for antifungal therapy. Chromoblastomycosis infections need to be treated with antifungal medication such as itraconazole, terbinafine,  posaconazole, amphotericin B. Often, the treatment for chromoblastomycosis requires surgery to scrape off the infected tissue. The growth of the Chromoblastomycosis treatment market is primarily driven by increasing incidents of fungal infections, rising prevalence of immunological diseases, availability of wide range of products, and increasing awareness about the fungal infections. However, the existence of misbranded drugs and their side effects may slow the growth of the market. The treatment of fungal infections is available in multiple dosage forms such as oral and intravenous medicines. Furthermore, the medications are also available in the form of sprays, creams, solutions, and shampoos.


The chromoblastomycosis treatment market is expected to grow at a CAGR of approximately 6.3% during the forecast period, 2017-2023.


Research Methodology


 chromoblastomycosis treatment Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience



  • Chromoblastomycosis treatment Drug Suppliers

  • Chromoblastomycosis treatment Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The chromoblastomycosis treatment market is segmented on the basis of species, types, diagnosis, treatment, and end-users.


On the basis of the species, the chromoblastomycosis treatment market is segmented into Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola, and others.


On the basis of the disease type, the chromoblastomycosis treatment market is segmented into nodular type, tumoral type, verrucous type, plaque type, and others.


On the basis of the diagnosis, the chromoblastomycosis treatment market is segmented into blood test, immunodiagnosis, histopathology and mycological examination, tissue biopsy, and others. The immunodiagnosis is classified into enzyme-linked immune sorbent assay (ELISA), and immunodiffusion, and others.


On the basis of the treatment, the chromoblastomycosis treatment market is segmented into surgery, antifungal drugs, amphotericin B therapy, thermotherapy, laser therapy, photodynamic therapy, adjuvant therapy, and others. The surgery is classified into cryosurgery, curettage, electrodesiccation, surgical excisions, and others. Furthermore, the antifungal drugs are categorized into oral itraconazole, oral terbinafine, posaconazole, isavuconazole, and others.


On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.


Regional Analysis                     


The chromoblastomycosis treatment market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East & Africa.


The Americas dominate the chromoblastomycosis treatment market owing to a huge patient population for chromoblastomycosis and well-developed healthcare sector. This disease commonly affects the agricultural workers in rural regions of South America, Central America, and North America.


The European region is the second largest market for the chromoblastomycosis treatment owing to the rising occurrence of fungal infections among the patients, and advancements in the surgeries procedure and the use of surgical devices. It was estimated that about 20% of these cases were found in countries such as the Czech Republic, Romania, and Finland.


Asia Pacific is the fastest growing region for chromoblastomycosis treatment market due to increasing prevalence of fungal infections, and regional expansion for the development of this market. Japan is considered to exhibit the highest prevalence rate for chromoblastomycosis in the Asia Pacific region.


The Middle East & Africa region contributed the lowest share of the chromoblastomycosis treatment market, in 2016. Several different Latin American and the African countries, such as Colombia, Gabon, Venezuela, the Dominican Republic, and Cuba, have high prevalence rates for this condition.


Key Players


Some of key the players in the chromoblastomycosis treatment market are Astellas Pharma (Japan), Biocon Limited (India),  Abbott Laboratories (U.S.), Merck Sharp and Dohme (U.S.), Gilead Sciences (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switzerland), Sanofi (France), F. Hoffman La Roche (Switerzland), Cadila Pharmaceuticals Limited (India),  Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switerzland), and others



Speak to Analyst Ask for Customization